Rho Kinase Inhibitor Therapy for Frontotemporal Dementia Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no approved drugs for the management of frontotemporal dementia (FTD), a progressive neurodegenerative syndrome characterized by atrophy of the prefrontal and anterior temporal cortices, and current treatments for related conditions like vascular dementia are not effective for cortical regions of the brain.
Innovation Solution
Administering a pharmacologically effective amount of the rho kinase inhibitor fasudil or its pharmaceutically acceptable salts to patients with FTD, particularly those with behavioral variant frontotemporal dementia (bvFTD), to target tau or TDP-43 aggregates and alleviate symptoms such as behavioral changes, cognitive deficits, and cerebral atrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no approved drugs are used for FTD management, then current treatment options remain limited, but patient symptoms and cerebral atrophy progress without effective intervention
Solution Approach 1:
The patent applies parameter changes by introducing a novel pharmacological agent (fasudil, a rho kinase inhibitor) with a mechanism of action different from existing dementia treatments. This drug targets rho kinase activity to reduce cerebral atrophy and improve symptoms, representing a change in the pharmacological parameters available for FTD treatment.
2Object-affected harmful factors
If vasodilator drugs like fasudil are used for vascular dementia, then wandering symptoms may improve, but the drugs are not effective for cortical regions affected in FTD
Solution Approach 1:
The patent demonstrates universality by showing that fasudil, originally developed for vascular dementia, can also be effective for FTD. The drug's ability to inhibit rho kinase and reduce atrophy in cortical regions makes it applicable across different dementia types, expanding its therapeutic versatility.
Solution Approach 2:
The patent applies parameter changes by utilizing fasudil's rho kinase inhibitory properties to address cortical atrophy in FTD, transforming a drug designed for vascular applications into an effective treatment for neurodegenerative cortical diseases through its mechanism of reducing atrophy.
3Ease of operation
If FTD is treated with symptomatic management only, then disease progression continues, but no effective disease-modifying treatment is available
Solution Approach 1:
The patent applies preliminary action by using fasudil to prevent or slow cerebral atrophy before severe neurological damage occurs. The rho kinase inhibitor acts early in the disease process to reduce atrophy and potentially delay progression, rather than only managing established symptoms.
Data Source
AI summary
The present invention relates to methods of treating frontotemporal dementia. The methods are preferably accomplished by treatment with a rho kinase inhibitor, such as fasudil or hydroxyfasudil. In particular, the invention contemplates treatment of the behavioral variant frontotemporal dementia and usually treatment begins once symptoms become evident. Usually, patients treated according to the invention have no neuromuscular symptoms and generally have not been diagnosed with amyotrophic lateral sclerosis, corticobasal degeneration, Parkinson's Disease or progressive supranuclear palsy. A preferred method of the invention involves oral treatment with fasudil, administered in a total daily dose of between 70 mg and 140 mg.